comprehensive -WSS

comprehensive

author：entertainment 2025-09-27 23:00:45 - browse：736

Buildings like hospitals and banks on a web with people operating laptops and phones — health tech coverage from STAT — Adobe

For years, the playbook for many companies that wanted to market digital therapeutics was stupid simple: Sell it like a prescription drug.

But just because it was simple didn’t mean it was going to work.

The bankruptcy of Pear Therapeutics last year proved that selling software-based treatments like drugs is harder than anticipated. Pear received Food and Drug Administration clearance for its app treating substance use disorders and insomnia but insurers mostly refused to cover the novel treatments. Even after hitting roadblock after roadblock, the company stuck to its original plan and ended up vaporizing over $400 million in investment before finally throwing in the towel.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Trump surgeon general acknowledges mistakes during Covid

WSS

Illumina names Agilent executive as new CEO

Covid hospitalizations on the rise, Humana says

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

How to fix cancer clinical trials' diversity problem

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Hospitals consider fixing cancer drug shortages on their own

Wikipedia

comprehensive

knowledge

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Illumina names Agilent executive as new CEO

Guidelines to prevent youth baseball injuries need more muscle

WATCH: Why do bright lights make us see spots?

Activists slam private health insurers over coverage restrictions

Diverse clinical trials: Why aren’t we there yet?

Virginia high school admissions case could be legal follow

How housing is health care on Long Island

Hollywood unions extend contract negotiations for actors

Stem cell treatment guidelines are released by FDA

focus

What to make of Biden’s latest efforts on cancer research

Illumina names Agilent executive as new CEO

Food makers tried to stack nutrition panel with preferred experts

How to make the FDA’s new prescription one

Will the IRA bring competition to the biologics market?

House transparency, PBM reform bill gains bipartisan support

Wikipedia

leisure time

hotspot

focus